Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017152032) NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS Β-CATENIN MODULATORS AND USES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/152032 International Application No.: PCT/US2017/020631
Publication Date: 08.09.2017 International Filing Date: 03.03.2017
IPC:
A61K 31/426 (2006.01) ,A61K 31/42 (2006.01) ,A61K 31/421 (2006.01) ,A61P 35/00 (2006.01) ,C07K 16/28 (2006.01)
[IPC code unknown for A61K 31/426][IPC code unknown for A61K 31/42][IPC code unknown for A61K 31/421][IPC code unknown for A61P 35][IPC code unknown for C07K 16/28]
Applicants:
NEW YORK UNIVERSITY [US/US]; 70 Washington Square South New York, NY 10012, US
Inventors:
DASGUPTA, Ramanuj; US
RAJULU, Gavara, Govinda; IN
DICKSON, John, K.; US
Agent:
FASHENA, Sarah, J.; US
Priority Data:
62/303,42704.03.2016US
Title (EN) NOVEL OXAZOLE AND THIAZOLE COMPOUNDS AS Β-CATENIN MODULATORS AND USES THEREOF
(FR) NOUVEAUX COMPOSÉS OXAZOLES ET THIAZOLES POUVANT ÊTRE UTILISÉS COMME MODULATEURS DE LA Β-CATÉNINE ET LEURS UTILISATIONS
Abstract:
(EN) Heterocyclic compounds according to formula I: wherein A, B, Y, and Cy are as described herein, are provided as inhibitors of the Wnt pathway that specifically target the activity of the stabilized pool of B-cat. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, cancer, and other conditions related to Wnt pathway dysfunction, including various cancers and pulmonary fibrosis.
(FR) Des composés hétérocycliques selon la formule I : dans laquelle A, B, Y et Cy sont tels que décrits dans l'invention, sont utilisés en tant qu'inhibiteurs de la voie Wnt qui ciblent spécifiquement l'activité du pool stabilisé de B-cat Lesdits composés peuvent être préparés sous forme de compositions pharmaceutiques et peuvent être utilisés dans la prévention et le traitement de divers états chez les mammifères, notamment les hommes, comprenant et de manière non restrictive le cancer et d'autres états liés à un dysfonctionnement de la voie Wnt, notamment divers cancers et la fibrose pulmonaire.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)